All drugs were provided at the starting dose recommended by the manufacturer and were placed in identical capsules that matched the placebo capsules administered during the run-in phase of the study.
Please enable scripts and reload this page. You may be trying to access this site from a secured browser on the server.
Least squares mean change from baseline in cuff diastolic blood pressure DBP after 8 weeks of treatment with olmesartan, losartan, valsartan, and irbesartan. Tolerability Olmesartan generally is well tolerated. Patients treated with olmesartan experienced a mean reduction in cuff SBP of At 2 weeks mean SBP was reduced by Aug 15, Issue.
There were no significant differences among groups in the overall incidence of laboratory adverse events, or in the incidence of adverse events within any body system.
The duration and consistency of hour blood pressure control were estimated by determining the DBP and SBP trough-to-peak ratios after 8 weeks of treatment.
Close article support pane. Values for olmesartan were taken from previous registrational trials performed by Sankyo Pharma Sankyo Pharma, data on file, The mean reduction in cuff DBP achieved with olmesartan Olmesartan reduced mean hour SBP by Upper respiratory infection, headache, fatigue, back pain, and dizziness were the most common complaints.
Over the 8-week treatment period, therapy with olmesartan also resulted in a mean reduction of SBP of Your message has been successfully sent to your colleague.
Clinical efficacy of olmesartan medoxomil. The overall incidence of adverse events was comparable among the four treatment groups. The ABPM devices were programmed to record blood pressure every 15 minutes throughout a hour period.
Medical Economics Data, Adverse event data are presented for the period of active treatment only and all randomized patients are included. In the opinion of the investigator, these events were not related to the study drugs. The reduction in mean hour SBP with olmesartan The required sample size of the treatment groups was estimated by assuming that the decrease in cuff sitting DBP during treatment with olmesartan would be 4.